Bioarray Genetics Receives $4M in Series B Equity Financing

Bioarray Genetics, a personalized medicine startup, announced today that it has received $4 million in Series B Equity Financing from Quark Venture and GF Securities through their Global Health Science Fund and Connecticut Innovations.

Bioarray, a personalized medicine startup housed at UConn’s Technology Incubation Program (TIP) in Farmington, is a molecular diagnostics company developing predictive cancer treatment test technology. The platform, consisting of unique genes and proprietary algorithms, provides patient-specific information to determine the optimal course of treatment.
Bioarray will use this funding to bring their first product, BA100, to clinicians and conduct R&D on other tests in the company’s pipeline, including those focused on treatments for metastatic breast and colon cancers.

Read the full article here.

2018-04-26T20:52:13+00:00